Orbital relapse of retinoblastoma in patients with high-risk histopathology features.

eye orbital tumors retinoblastoma tumor

Journal

Therapeutic advances in ophthalmology
ISSN: 2515-8414
Titre abrégé: Ther Adv Ophthalmol
Pays: United States
ID NLM: 101728805

Informations de publication

Date de publication:
Historique:
received: 18 02 2019
accepted: 21 03 2019
entrez: 9 5 2019
pubmed: 9 5 2019
medline: 9 5 2019
Statut: epublish

Résumé

To describe the clinical picture of orbital relapse of retinoblastoma following uncomplicated enucleation. Case series of two patients with group E retinoblastoma with high-risk features on histopathology, namely, post-laminar optic nerve extension in one patient, and massive choroidal tumor infiltration in the other. Neither of them received adjuvant chemotherapy post enucleation. Both patients had orbital relapse of tumor within 4 months from enucleation, manifesting as implant migration and unstable conformer. Systemic chemotherapy and external beam radiotherapy to the orbit resulted in complete tumor regression. Both patients were tumor free at the last follow up. Implant migration post enucleation should raise the suspicion for orbital relapse of retinoblastoma. High-risk histopathology features should increase the alert in an otherwise uncomplicated enucleation for retinoblastoma.

Identifiants

pubmed: 31065625
doi: 10.1177/2515841419844080
pii: 10.1177_2515841419844080
pmc: PMC6487749
doi:

Types de publication

Case Reports

Langues

eng

Pagination

2515841419844080

Déclaration de conflit d'intérêts

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Ophthalmology. 2000 May;107(5):940-5; discussion 946
pubmed: 10811087
J Pediatr Ophthalmol Strabismus. 2000 May-Jun;37(3):134-41; quiz 168-9
pubmed: 10845413
Cancer. 2003 Sep 15;98(6):1292-8
pubmed: 12973854
Br J Ophthalmol. 2004 Aug;88(8):1069-73
pubmed: 15258027
Br J Ophthalmol. 2004 Aug;88(8):1074-7
pubmed: 15258028
Ophthalmol Clin North Am. 2005 Mar;18(1):41-53, viii
pubmed: 15763190
Clin Exp Ophthalmol. 2005 Aug;33(4):386-9
pubmed: 16033351
Br J Ophthalmol. 2009 Apr;93(4):463-7
pubmed: 18757474
Curr Opin Ophthalmol. 2010 May;21(3):203-12
pubmed: 20224400
Can J Ophthalmol. 2010 Dec;45(6):606-9
pubmed: 20935691
Lancet. 2012 Apr 14;379(9824):1436-46
pubmed: 22414599
Arch Ophthalmol. 1990 Jan;108(1):128-32
pubmed: 2288550
Br J Ophthalmol. 1990 Feb;74(2):97-8
pubmed: 2310733
Middle East Afr J Ophthalmol. 2014 Oct-Dec;21(4):321-7
pubmed: 25371638
Ophthalmic Genet. 2015;36(3):287-9
pubmed: 25945688
Acta Ophthalmol. 2016 Mar;94(2):165-74
pubmed: 26603132
Ophthalmology. 2016 Mar;123(3):635-45
pubmed: 26692298
Br J Ophthalmol. 1989 Sep;73(9):739-42
pubmed: 2804029
Hematol Oncol Clin North Am. 1987 Dec;1(4):721-35
pubmed: 3323180
Ophthalmic Paediatr Genet. 1987 Mar;8(1):63-8
pubmed: 3587891
Trans Am Ophthalmol Soc. 1974;72:79-88
pubmed: 4462255
Br J Ophthalmol. 1979 Aug;63(8):560-70
pubmed: 476032
Cancer. 1994 Feb 1;73(3):692-8
pubmed: 8299091
Ophthalmic Plast Reconstr Surg. 1998 Jan;14(1):37-44
pubmed: 9513242

Auteurs

Maria Vittoria Cicinelli (MV)

Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India.

Swathi Kaliki (S)

Operation Eyesight Universal Institute for Eye Cancer, L V Prasad Eye Institute, Hyderabad, India.

Classifications MeSH